PMID- 20082586
OWN - NLM
STAT- MEDLINE
DCOM- 20100423
LR  - 20221207
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 12
IP  - 1
DP  - 2010 Jan
TI  - Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 
      diabetes mellitus.
PG  - 57-64
LID - 10.1089/dia.2009.0129 [doi]
AB  - BACKGROUND: A progressive weight gain is associated with various pharmacological 
      options improving glycemic control in type 2 diabetes mellitus (T2DM). Ghrelin 
      has been implicated in the regulation of feeding behavior and energy balance in 
      humans. Based on evidence that functional ATP-sensitive channels are present in 
      ghrelin-producing cells, we hypothesized that meglitinides may affect circulating 
      ghrelin levels in subjects with type 2 diabetes. METHODS: In a single-blinded 
      randomized three-period crossover study (n = 20), repaglinide or nateglinide was 
      given in combination with metformin for two treatment periods over a 1-week 
      period, respectively, separated by a 1-week treatment with placebo. Liquid meal 
      challenge tests (LMCTs) with single preprandial doses of repaglinide (2 mg), 
      nateglinide (120 mg), or placebo were performed at the end of each treatment 
      period. Ten control subjects without diabetes underwent a single LMCT without any 
      medication. RESULTS: Fasting ghrelin concentrations were not different between 
      all treatments and between patients with diabetes and control subjects. Subjects 
      with T2DM treated with placebo showed no suppression of ghrelin in the LMCT. 
      After administration of meglitinides a nadir of serum ghrelin was observed at 60 
      min (8.6% of baseline [P = 0.038] for repaglinide and 7.5% of baseline [P = 
      0.081] for nateglinide), which was similar to the secretion pattern seen in 
      control subjects. No correlations between postprandial insulin or glucose levels 
      and circulating ghrelin concentrations were observed. CONCLUSIONS: Treatment with 
      meglitinides reconstructed postprandial ghrelin secretion patterns to those of 
      controls without diabetes. This observation may help to improve the control of 
      feeding behavior in patients with T2DM.
FAU - Rudovich, Natalia
AU  - Rudovich N
AD  - Department of Clinical Nutrition, German Institute of Human Nutrition 
      Potsdam-Rehbrucke, 14558 Nuthetal, Germany. rudovich@dife.de
FAU - Mohlig, Matthias
AU  - Mohlig M
FAU - Otto, Barbel
AU  - Otto B
FAU - Pivovarova, Olga
AU  - Pivovarova O
FAU - Spranger, Joachim
AU  - Spranger J
FAU - Weickert, Martin O
AU  - Weickert MO
FAU - Pfeiffer, Andreas F H
AU  - Pfeiffer AF
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Benzamides)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Carbamates)
RN  - 0 (Ghrelin)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Piperidines)
RN  - 668Z8C33LU (repaglinide)
RN  - 8V6OK1I088 (meglitinide)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Benzamides/*therapeutic use
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - C-Peptide/blood
MH  - Carbamates/therapeutic use
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Eating
MH  - Feeding Behavior
MH  - Ghrelin/*blood/metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/blood
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Piperidines/therapeutic use
MH  - Reference Values
MH  - Single-Blind Method
EDAT- 2010/01/20 06:00
MHDA- 2010/04/24 06:00
CRDT- 2010/01/20 06:00
PHST- 2010/01/20 06:00 [entrez]
PHST- 2010/01/20 06:00 [pubmed]
PHST- 2010/04/24 06:00 [medline]
AID - 10.1089/dia.2009.0129 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2010 Jan;12(1):57-64. doi: 10.1089/dia.2009.0129.